Quarfloxin

Drug Profile

Quarfloxin

Alternative Names: CS-3543; CX-3543; Itarnafloxin

Latest Information Update: 11 Mar 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cylene Pharmaceuticals
  • Class Antineoplastics; Fluoroquinolones; Small molecules
  • Mechanism of Action Apoptosis stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Neuroendocrine tumours

Most Recent Events

  • 06 Mar 2013 Quarfloxin licensed to TetraGene
  • 30 Jun 2010 Discontinued - Phase-II for Neuroendocrine tumours in USA (IV)
  • 03 Nov 2008 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top